Cargando…
Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Peritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma, or seco...
Autores principales: | VALLEJO, JAIRO SEBASTIÁN ASTUDILLO, QUEIROZ, FABIO LOPES DE, LACERDA, ANTÔNIO, FRANÇA, PAULO ROCHA, COSTA, BRENO XAIA MARTINS DA, PAIVA, RODRIGO ALMEIDA, GARCIA, SILVÉRIO LEONARDO MACEDO, SILVA, SERGIO BOTREL |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Colégio Brasileiro de Cirurgiões
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508679/ https://www.ncbi.nlm.nih.gov/pubmed/37075463 http://dx.doi.org/10.1590/0100-6991e-20233421-en |
Ejemplares similares
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004) -
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
por: Ellison, Lynne M., et al.
Publicado: (2017) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
por: Roh, Seung Jae, et al.
Publicado: (2020) -
The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
por: Hung, Hao-Chien, et al.
Publicado: (2021) -
Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Rodt, Anne Peen, et al.
Publicado: (2013)